These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Rai BP; Cody JD; Alhasso A; Stewart L Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594 [TBL] [Abstract][Full Text] [Related]
30. Specific Changes in Brain Activity during Urgency in Women with Overactive Bladder after Successful Sacral Neuromodulation: A Functional Magnetic Resonance Imaging Study. Weissbart SJ; Bhavsar R; Rao H; Wein AJ; Detre JA; Arya LA; Smith AL J Urol; 2018 Aug; 200(2):382-388. PubMed ID: 29630979 [TBL] [Abstract][Full Text] [Related]
31. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568 [TBL] [Abstract][Full Text] [Related]
32. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation. Elmer-Lyon CG; Streit JA; Takacs EB; Ten Eyck PP; Bradley CS Int Urogynecol J; 2020 May; 31(5):871-879. PubMed ID: 31222571 [TBL] [Abstract][Full Text] [Related]
33. Re: OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. Cornu JN Eur Urol; 2017 Jun; 71(6):988-989. PubMed ID: 28249800 [No Abstract] [Full Text] [Related]
34. Sacral Neuromodulation: Determining Predictors of Success. Morgan TN; Pace N; Mohapatra A; Ren D; Kunkel G; Tennyson L; Shepherd JP; Chermansky CJ Urology; 2021 Jul; 153():124-128. PubMed ID: 32619594 [TBL] [Abstract][Full Text] [Related]
35. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C; J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773 [TBL] [Abstract][Full Text] [Related]
36. Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women. Hendrickson WK; Xie G; Rahn DD; Amundsen CL; Hokanson JA; Bradley M; Smith AL; Sung VW; Visco AG; Luo S; Jelovsek JE Neurourol Urodyn; 2022 Jan; 41(1):432-447. PubMed ID: 34859485 [TBL] [Abstract][Full Text] [Related]
37. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial. Herschorn S; Kohan A; Aliotta P; McCammon K; Sriram R; Abrams S; Lam W; Everaert K J Urol; 2017 Jul; 198(1):167-175. PubMed ID: 28161352 [TBL] [Abstract][Full Text] [Related]
38. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C; J Urol; 2013 Jun; 189(6):2186-93. PubMed ID: 23246476 [TBL] [Abstract][Full Text] [Related]
39. Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation. Timm B; Jayarajan J; Chan G; Bolton D Low Urin Tract Symptoms; 2021 Jan; 13(1):194-197. PubMed ID: 32548938 [TBL] [Abstract][Full Text] [Related]
40. Axonics® system for treatment of overactive bladder syndrome and urinary urgency incontinence. Wang A; Rourke E; Sebesta E; Dmochowski R Expert Rev Med Devices; 2021 Aug; 18(8):727-732. PubMed ID: 34187274 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]